78
Participants
Start Date
January 11, 2012
Primary Completion Date
August 18, 2015
Study Completion Date
August 18, 2015
Laboratory Biomarker Analysis
Optional correlative studies
Placebo
Given PO
Tivantinib
Given PO
Roswell Park Cancer Institute, Buffalo
MedStar Georgetown University Hospital, Washington D.C.
University of Maryland/Greenebaum Cancer Center, Baltimore
University of Maryland Saint Joseph Medical Center, Towson
Moffitt Cancer Center, Tampa
Ohio State University Comprehensive Cancer Center, Columbus
Case Western Reserve University, Cleveland
Cleveland Clinic Foundation, Cleveland
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne
University of Wisconsin Hospital and Clinics, Madison
NorthShore University HealthSystem-Evanston Hospital, Evanston
Ingalls Memorial Hospital, Harvey
Northwestern University, Chicago
Michael Reese Hospital, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
Illinois CancerCare-Peoria, Peoria
Decatur Memorial Hospital, Decatur
Southern Illinois University School of Medicine, Springfield
Mercy Hospital Saint Louis, St Louis
National Cancer Institute (NCI)
NIH